Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006480 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma
A Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00006480: Completed Phase 1 study, sponsored by Fred Hutchinson Cancer Center.
NCT00006480 is a Phase 1 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006480, a Phase 1 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Inserting genetic material made in the laboratory into a person's blood cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of biological therapy and gene therapy in treating children who have recurrent or refractory neuroblastoma.
Interventions
- BIOLOGICAL therapeutic autologous lymphocytes
- BIOLOGICAL aldesleukin
- DRUG chemotherapy
- DRUG ganciclovir
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-05 |
| Est. Completion | 2005-03 |
| Phase | Phase 1 |
What the finished NCT00006480 record still lists
NCT00006480 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which therapeutic autologous lymphocytes is the first listed.
NCT00006480 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006480 about?
NCT00006480 is a clinical study titled "Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Inserting genetic material made in the laboratory into a person's blood cells may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effe...
What is the current status of trial NCT00006480?
This trial is currently completed. It is a Phase 1 study. The study started on 2000-05. Estimated completion is 2005-03.
What interventions are being tested in trial NCT00006480?
The interventions under investigation include: therapeutic autologous lymphocytes (BIOLOGICAL), aldesleukin (BIOLOGICAL), chemotherapy (DRUG), ganciclovir (DRUG).
Who is sponsoring clinical trial NCT00006480?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia